# Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer

> **NCT04158856** · PHASE2 · NOT_YET_RECRUITING · sponsor: **xuexin he** · enrollment: 60 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** Pyrotinib
- **DRUG:** Trastuzumab

## Key facts

- **NCT ID:** NCT04158856
- **Lead sponsor:** xuexin he
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2020-06-01
- **Primary completion:** 2023-05-31
- **Final completion:** 2030-05-31
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-11-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04158856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04158856, "Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04158856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*